<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645745</url>
  </required_header>
  <id_info>
    <org_study_id>UVittorio</org_study_id>
    <nct_id>NCT04645745</nct_id>
  </id_info>
  <brief_title>Myo-inositol, Alpha-Lactalbumin and Folic Acid Treatment in PCOS</brief_title>
  <official_title>Effects of Myo-inositol, Alpha-Lactalbumin and Folic Acid Treatment in PCOS Women of Mexico and Italy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGUNCO Obstetrics and Gynecology Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Juarez de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AGUNCO Obstetrics and Gynecology Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to evaluate the effect of myo-inositol and alpha-lactalbumin&#xD;
      treatment on HOMA-index improvement in two different groups of women, belonging to the&#xD;
      Mexican and Italian population, both affected by Polycystic Ovary Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label clinical trial aimed at evaluating and comparing the effect of&#xD;
      myo-inositol and alpha-lactalbumin treatment on HOMA-index improvement in two different&#xD;
      groups of PCOS patients from the Mexican and Italian population. The addition of&#xD;
      alpha-lactalbumin helps to increase the intestinal absorption of myo-inositol and&#xD;
      consequently improve its effect. The scientific evidence so far available shows that these&#xD;
      two groups of PCOS women have a different genetic, nutritional, and behavioural profile.&#xD;
      Important factors are body mass index and insulin resistance, both increased in the Mexican&#xD;
      women, although among them PCOS prevalence is not higher compared to many other populations.&#xD;
      Therefore, the focus of this study is to check the effects of the combined administration of&#xD;
      myo-inositol and alpha-lactalbumin for six months (with a control at three months) e to&#xD;
      compare these effects between the two groups of patients, monitoring several hormonal&#xD;
      parameters connected to the menstrual cycle regularization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2019</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Myo-inositol and alpha-lactalbumin treatment on HOMA-index</measure>
    <time_frame>three and six months</time_frame>
    <description>monitoring glucose and insulin levels in blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Myo-inositol and alpha-lactalbumin treatment on ovulation</measure>
    <time_frame>three and six months</time_frame>
    <description>dosage of Progesterone, LH, FSH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Myo-inositol and alpha-lactalbumin treatment on hyperandrogenism</measure>
    <time_frame>three and six months</time_frame>
    <description>dosage of Total Testosterone, Free Testosterone, Androstenedione.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>myo-inositol plus alpha-lactalbumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were treated with 2 g myo-inositol, 50 mg alpha-LA and 200 mcg of Folic Acid twice a day for 6 months. Controls were the same patients at baseline (t0)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>myo-inositol, alpha-lactalbumin, folic acid</intervention_name>
    <description>Evaluating the improvement vs the baseline after three and six months of treatment</description>
    <arm_group_label>myo-inositol plus alpha-lactalbumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PCOS diagnosis based on the Rotterdam ESHRE-ASRM consensus workshop group1.&#xD;
&#xD;
          -  Presence of Insulin resistance diagnosed by HOMA-Index&#xD;
&#xD;
          -  Patients belonging to the Mexican population&#xD;
&#xD;
          -  Patients belonging to the Italian population&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI ≥ 30&#xD;
&#xD;
          -  Other conditions causing ovulatory disorders and/or androgens hyper production such&#xD;
             as: hyperprolactinemia, hypothyroidism, adrenal hyperplasia and Cushing syndrome&#xD;
&#xD;
          -  Hormonal and/or pharmacological treatments in the previous 3 months that could&#xD;
             interfere with ovulation&#xD;
&#xD;
          -  Drastic changes in diet and physical activity&#xD;
&#xD;
          -  Treatment with products containing inositols in the previous 3 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AGUNCO Centre</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juarez de México</name>
      <address>
        <city>Ciudad de México</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AGUNCO Obstetrics and Gynecology Centre</investigator_affiliation>
    <investigator_full_name>Unfer Vittorio</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Myo-inositol</keyword>
  <keyword>alpha-lactalbumin</keyword>
  <keyword>HOMA-index</keyword>
  <keyword>ovulation</keyword>
  <keyword>hyperandrogenism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

